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Multipotent mesenchymal stem cells with extensive self-renewal properties can be easily isolated and rapidly expanded in culture
from small volumes of amniotic fluid. These cells, namely, amniotic fluid-stromal cells (AFSCs), can be regarded as an attractive
source for tissue engineering purposes, being phenotypically and genetically stable, plus overcoming all the safety and ethical
issues related to the use of embryonic/fetal cells. LMP3 is a novel osteoinductive molecule acting upstream to the main osteogenic
pathways. This study is aimed at delineating the basic molecular events underlying LMP3-induced osteogenesis, using AFSCs as a
cellular model to focus on themolecular features underlying themultipotency/differentiation switch. For this purpose, AFSCs were
isolated and characterized in vitro and transfected with a defective adenoviral vector expressing the human LMP3. LMP3 induced
the successful osteogenic differentiation of AFSC by inducing the expression of osteogenic markers and osteospecific transcription
factors. Moreover, LMP3 induced an early repression of the kruppel-like factor-4, implicated in MSC stemness maintenance. KLF4
repression was released upon LMP3 silencing, indicating that this event could be reasonably considered among the basic molecular
events that govern the proliferation/differentiation switch during LMP3-induced osteogenic differentiation of AFSC.
1. Introduction
Cell-based strategies are widely used for tissue engineering
purposes, that is, to achieve the replacement, repair, and
restoration of tissue and organ functions. Somatic stem cells,
especially mesenchymal stromal cells (MSCs), represent the
most valuable resource to this aim, being mainly used in
orthopedics applications [1, 2]. MSCs, originally isolated
from bonemarrow, are multipotent cells, residing in the con-
nective stroma of different adult tissues and solid organs, and
capable to differentiate toward multiple mesodermal lineages
[3]. MSCs can be indeed isolated from different adult tissues
sources, including fat, skeletal muscle and skin [3–8]. Beside
adult tissues, more recently MSC have been isolated from
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fetal and perinatal fluids and tissues, including umbilical
cord (UC), chorionic villi (CV), and amniotic fluid (AF)
[9–11]. Particularly, amniotic fluid stromal cells (AFSCs)
can be regarded as attractive pluripotent stem cells, due to
the ease of isolation from small volumes of AF, their rapid
expansion in culture and their capability of extensive self-
renewal [11–13]. In addition, AFSCs appear phenotypically
and genetically stable after in vitro expansion, overcoming
all the safety issues related to the use of embryonic/fetal
cells [14]. The surface marker profile of AFSC suggests that
they represent an intermediate stage between embryonic
stem cells and adult MSC [11, 15]. In fact, AFSC retain the
ability to differentiate into cells of all three embryonic germ
layers along with higher growth kinetics than adult MSC
[3, 10, 13, 16]. These features makes AFSCs unique among
somatic stem cells and suggests their possibile application
in translational medicine, by-passing the common ethical
issues associated to embryonic stem cells.
Among the wide range of tested clinical applications of
AFSCs [17], their osteogenic potential has been particularly
investigated as a potentially relevant property, in the light
of the attractive results obtained in animal models of
skeletal regeneration ([18–20]). The complete network of
molecular signals involved in the osteogenic commitment
of MSCs has been partially defined. We have previously
demonstrated that the Kruppel-like factor family genes,
coding for DNA-binding proteins, play a crucial role in
maintaining MSC stemness and self-renewal properties by
transcription regulation and are progressively repressed
during MSC differentiation [21].
The LIMmineralization protein (LMP) is an intracellular
positive regulator of osteoblast differentiation that is able to
induce the osteogenic differentiation of MSC, by activating
the expression of genes that govern the balance between
cell proliferation/differentiation and are involved in skeletal
tissue development [22, 23]. LMP was originally isolated
from the rat calvaria and is present in three alternatively
spliced transcript variants, namely, LMP-1, -2, and -3,
in humans (GenBank accession numbers: AAK30567.1;
AAK30568.1, AAK30569.1, respectively, [24, 25]. The first
two transcript variants, LMP1 and LMP2, encoding the
full-length and intermediate protein isoforms, respectively,
contain both PDZ and LIM conserved domains in their
structure. LMP3 encode a truncated isoform and represent
the shortest variant [26]. Both LMP1 and LMP3 are
osteogenic and could represent promising molecular
tools for bone tissue-engineering applications, as recent
studies demonstrated that they act upstream to the main
osteogenic pathways [1, 22, 23, 27]. In particular, the most
functionally relevant molecular interactions involved in the
LMP1 osteogenic properties have been clarified in vitro,
while the LMP3-related osteogenic signalling is still poorly
understood.
The aim of this study was to assess the capability of
LMP3 to induce the osteogenic differentiation of AFSCs,
and to characterize the molecular events associated to this
process, focusing on the molecular features underlying the
multipotency/differentiation switch.
2. Materials and Methods
2.1. Cell Isolation and Culture. Amniotic fluid samples were
obtained by amniocentesis performed between 16 and 20
weeks of gestation for fetal karyotyping. Patients were
enrolled in the study upon signing a written informed
consent. All procedures employed in this study have been
approved by the Ethical Committee of the Catholic Univer-
sity of Rome, Italy (protocol number P552 (A.779/CE2007).
AFSCs were isolated from the diagnostic specimens using
a two-step culture protocol, saving the amniocytes needed
for chromosome analysis [3, 28]. Briefly, nonadherent cells
were collected by centrifugation from the culture medium
saved from amniocytes after 7 days of primary culture. Cells
were then plated in T25 tissue culture flasks at a seeding
density of 105 cells/cm2, using the Mesenchymal Stem Cell
Medium (MSCGM) (Lonza, Basel, Switzerland), and incu-
bated overnight in a humidified incubator at 37◦C and 5%
CO2. The following day, the medium was replaced to remove
nonadherent cells. Upon reaching 80% confluence, cells were
detached with trypsin/EDTA and further expanded. The
specific surface antigens of MSCs expressed on AFSC (at
culture passage 4 to 5) were investigated by flow cytometry
analysis, as previously described [3].
2.2. Adenoviral-Mediated Cell Transduction. Defective ade-
noviral vectors carrying the LMP-3 gene (AdLMP-3) were
constructed as previously described [23]. Subconfluent
AFSCs were transduced within the 3rd culture passage
with 100 pfu/cell of AdLMP-3 vector. Mock-transfected cells,
that is, cells infected with an empty adenoviral vector (the
viral vector backbone, termed AdΨ5), served as negative
transduction controls. Transduction efficiency was evaluated
by means of RT-PCR as already described elsewhere [1]. Ad-
transduced cells were then used in time-course experiments
aimed at analyzing the expression of selected genes and
studying the morphological modifications induced by LMP3
overexpression.
2.3. In-Vitro Mineralization Assay. To evaluate the occur-
rence of osteogenic commitment and differentiation of
cells upon LMP3 overexpression, AFSCs were alternatively
transfected with either AdLMP-3 or AdΨ5. AFSCs cultured
in an osteogenic medium (OM, see [3] for protocol details)
served as positive controls for in vitro differentiation and
qPCR. Osteogenic differentiation was assessed after 2 weeks
by alizarin red staining, as previously described [3].
2.4. RNA Isolation. The total RNA was isolated from both
AdLMP3- amd AdΨ5-transduced AFSCs, at 1, 2, 4, and
7 days post-transduction, and from positive control cells
following 2 and 7 days of osteogenic induction, using the
RNeasy mini kit (Qiagen, Hilden, Germany), according to
the manufacturer’s suggested procedures. An additional on-
column DNase incubation step was performed, allowing
the selective removal of genomic DNA during the isolation
process. RNA was quantified using a UV spectrophotometer
and RNA quality and integrity were assessed Agilent 2100
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Bioanalyzer (Agilent, Santa Clara, CA, USA). One micro-
gram of RNA was reverse transcribed into cDNA using the
Superscript III (Invitrogen, Carlsbad, CA, USA).
2.5. Gene Expression Analysis. In order to clarify the molec-
ular events underlying the LMP3-mediated AFSC differen-
tiation, we have selected downstream acting genes involved
in the differentiation process and analyzed their expression
using quantitative real time PCR. In particular, we have
focused on the osteospecific transcription factors, Runt-
related transcription factor 2 (RUNX2) and Osterix (OSX),
and on the osteospecific genes bone morphogenetic protein
2 (BMP2), Osteocalcin (OC), and Osteopontin (OP). In
addition, we have analyzed the expression of the SWI/SNF-
related, matrix associated, actin-dependent regulator of
chromatin, C2 (SMARCC2). This gene encodes a protein
member of the chromatin remodeling complex, which was
involved in the osteogenic commitment of MSCs [29] and
was selected based on previous data suggesting that the
LMP3 could directly induce its expression in MSCs (Lattanzi
et al., unpublished observation). In addition, in order to
assess if LMP3 could alter the molecular control of stem
cell self-renewal and maintenance, we have analyzed the
expression of the Kruppel-like factor genes KLF-2 and KLF-4
[21, 30, 31].
Gene expression was analysed in transduced and control
cells 1, 2, 4, and 7 days after adenoviral transduction, using
quantitative real-time PCR. The assays were carried out in
triplicate using Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster city, CA, USA), on a StepOne instrument
(Applied Biosystems, Foster city, CA, USA). Thermocycling
conditions were as follows: an initial denaturation step
at 95◦C for 20 sec followed by 40 cycles at 95◦C for
1 sec and 60◦C for 20 sec (annealing and extension).
Primer sequences were designed using the Primer3 software
(http://frodo.wi.mit.edu/primer3/) and reported in Table 1.
The 2−ΔΔCt method [32] was applied to calculate fold
differences (fold change, FC) in gene expression, using the
gene Actin-beta (B-ACT) as the housekeeping reference
for data normalization. PCR products were subjected to
melting curve analysis to rule out the synthesis of unspecific
products.
2.6. LMP Transient Silencing. In order to clarify the influ-
ence of LMP on KLF-2 and -4 transcriptional modu-
lation, LMP expression was silenced in AFSCs using a
specific custom-designed double-strand small interfering
RNA (siRNA) construct (QIAGEN, Hilden, Germany). The
sequence of the anti-LMP siRNA construct was as follows:
5′-ATGCGGGTAGCCTCACACACA-3′, aligning on LMP
gene sequence from base position 170 to 190. For the
silencing assay, AFSCs were plated in 24 well plates at a
density of 2× 104 cells/well and incubated under standard
growth conditions. On next day, cells were transfected
with LMP-siRNA construct, complexed with Lipofectamine
RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA,
USA), according to the manifacturer’s suggested proce-
dure. Briefly, 0.5 μg of siRNA construct were diluted in
Table 1: Sequences of oligonucleotide primer used in qPCR.
Gene symbol Sense∗ Sequence
B-ACT
Fw 5′-TCGTGCGTGACATTAAGGAG-3′
Rv 5′-CCATCTCTTGCTCGAAGTCC-3′
BMP2
Fw 5′-CGTGTCCCCGCGTGCTTCTT-3′
Rv 5′-CGGCCACCATGGTCGACCTT-3′
KLF2
Fw 5′-GGCTTGTGATGCCTTGTGA-3′
Rv 5′-TGCCCACCTGTCTCTCTATGT-3′
KLF4
Fw 5′-GACCACCTCGCCTTACACAT-3′
Rv 5′-CCCCCAACTCACGGATATAA-3′
LMP
Fw 5′-AGCATCGATGGCGAGAAT-3′
Rv 5′-CCGGATCTTGTTCTGAGCTT-3′
OC
Fw 5′-GACTGTGACGAGTTGGCTGA-3′
Rv 5′-AGCAGAGCGACACCCTAGAC-3′
OP
Fw 5′-TGAAACGAGTCAGCTGGATG- 3′
Rv 5′-GCTCTCATCATTGGCTTTCC-3′
OSX
Fw 5′-TAGACACCATGACCCCATCA-3′
Rv 5′-CATGGCAACAGGGGATTAAC-3′
RunX2
Fw 5′-GATGTGCCTAGGCGCATT-3′
Rv 5′-AAAAGGGCCCAGTTCTGA-3′
SMARCC2
Fw 5′-CAGACATCTCTCCCCCTCAC-3′
Rv 5′-CTGGAACCGTGATGTCCAC-3′
∗
: Fw: forward (left) primer; Rv: reverse (right) primer.
culture medium, thereafter, 1/10 volume of Lipofectamine
RNAiMAX was added to the diluted siRNA and incubated
for 10–15 minutes at room temperature. The complexes
were diluted in 700 μL of fresh culture medium and added
to adherent cells. AFSCs transfected with a cocktail of
negative control siRNA constructs (AllStars Negative Control
siRNA, Qiagen) and cells treated with transfection reagent
alone served as gene silencing sham and scramble controls,
respectively. All experiments were carried out in triplicate in
order to test the reproducibility.
The silencing efficiency of siRNA construct was evaluated
by quantifying the expression of LMP gene in qPCR (see
Section 2.5) 24 and 48 hours following cell transfection. The
expression of KLF genes was also analyzed at the same time
points.
2.7. Detection of miR143/145. In order to investigate the
relation between TGFβ-1 and KLF4 during the LMP3-
mediated osteogenic commitment, the expression levels of
miR143/145 were analyzed in AdLMP3 transduced AFSCs,
using untransduced cells and AdΨ5 mock-transduced cells
as controls.
For this purpose, total RNA was isolated 24 and 48
hours after transfection with Ad-LMP3 and Ad-Ψ5, using
the mirVana miRNA Isolation Kit (Ambion, Austin, TX,
USA), following the manifacturer’s suggested procedure
for small RNAs enrichment. RNA was quantified using a
UV spectrophotometer. 0.5 μg of RNA was then reverse
transcribed using the miScript Reverse Transcription Kit
(QIAGEN).
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Figure 1: Transduction efficiency. RT-PCR showing transgenic
LMP-3 expression (visible bands) up to 72 hours after cell
transduction. No transgene expression can be detected in the
control cells transduced with AdΨ5.
The expression levels of miR143 and miR145 were
analyzed using the miScript SYBR Green PCR Kit and
miScript Primer Assays (QIAGEN, Hilden, Germany). Six
control miRNA, included in the miScript PCR Control Set
(QIAGEN), were amplified in real time PCR, as reference
controls for data normalization. The real-time PCR reac-
tion was carried out on the StepOne instrument (Applied
Biosystems, Foster city, CA, USA), using the following
thermocycling conditions: an initial activation step at 95◦C
for 15 min followed by 40 cycles at 94◦C for 15 sec, 55◦C
for 30 sec, and 70◦C for 30 sec (denaturation, annealing
and extension). The 2−ΔΔCt method [32] was applied to
calculate fold differences in gene expression as previously
described (see Section 2.5). PCR products were subjected to
melting curve analysis to rule out the synthesis of unspecific
products.
3. Results
3.1. Isolation and Characterization of AFMSCs. Adherent
cells were efficiently isolated from AF as soon as 2-to-
5 days after sample plating. The primary cellular popula-
tion was heterogeneous, with elongated thin cells and flat
rounded cells. Upon the first passage, all cells displayed a
homogeneous adherent fibroblast-like morphology, being
bipolar, spindle-shaped cells. The cells exhibited a homoge-
nous “mesenchymal” immunophenotype: CD73+, CD90+,
CD133+, cKit-.
3.2. hLMP-3 Gene Transfer Induces Osteogenic Differentiation
of AFSCs In Vitro. The transduction efficiency was evaluated
by means of RT-PCR to measure the transgenic LMP3
expression, using sequence-specific oligonucleotide primers.
An intense PCR band of the expected size was observed at
each tested time point in cells transduced with AdLMP3,
indicating an efficient and stable transgene expression
(Figure 1).
Alizarin staining was used to assess the osteogenic
differentiation in vitro in AFSC overexpressing LMP3 com-
pared to mock-transduced cells. Two weeks after AdLMP3
transduction, AFSC produced a diffuse red-stained min-
eralized matrix, as demonstrated by alizarin red staining
(Figure 2(a)). Cells cultured in OM displayed a comparable
degree of matrix mineralization in vitro (data not shown).
Conversely, no evident signs of osteogenic differentiation
were observed in mock transduced cells at the same tested
time point (Figure 2(b)).
3.3. LMP-3 Induces the Osteogenic Differentiation of AFSCs
by Inactivation of KLF Genes and Further Upregulation of
Osteospecific Transcription Factors and Bone Marker Genes.
In order to investigate the molecular effects of LMP3-
mediated bone induction, we examined the expression
level of genes associated with stemness maintenance and
osteoblastic reprogramming. The analysis revealed that
LMP-3 induced a significant and time-related upregulation
of osteospecific markers. In particular, the level of BMP2,
increased 2.5 folds (P < 0.05) and more than 10 folds (P <
0.05) in Ad-LMP3 transduced compared to AdΨ5-treated
cells, at day 4 and 7 after transduction, respectively. No
significant modulation of BMP2 expression was observed at
the earliest tested time points (day 1 and day 2; Figure 3(a)).
Interestingly, the expression of BMP2 in cells treated for 7
days with the OM (FC: 4.9; P < 0.05) was lower than that
induced by LMP3 (FC: 10.9; P < 0.05). No significant mod-
ulation of BMP2 expression was observed in cells cultured
in OM at the earliest time points (Figure 3(a)). RunX2 was
significantly (P < 0.05) upregulated in both OM-treated
and LMP3-overexpressing cells, compared to control mock-
transfected ones, from day 2 on. Conversely, no signficant
modulation was observed at day 1 (Figure 3(b)). Particularly,
at day 7, also in this case, a higher upregulation (FC: 9.8;
P < 0.05) was observed at day 7 in LMP3-transfected cells,
compared to OM-treated cells (FC: 6; P < 0.05; Figure 3(b)).
Also, the SMARCC2 gene resulted significantly upregulated
from day 2 on, in both OM-treated cells and AdLMP-3
overexpressing ones (Figure 3(c)). In particular, the increase
in SMARCC2 gene expression showed a time-related trend
in the AdLMP-3 group and reached the highest value (FC >
20; P < 0.05 Figure 3(c)) at day 7, when it was 4-fold
higher than in the OM group (Figure 3(c)). The OC gene
expression did not vary at either day 1 or day 2, in any
experimental group while increased significantly in AdLMP-
3-transduced cells at day 4 (FC: 2.2, P < 0.05) and day 7
(FC: 5.4, P < 0.05; Figure 3(d)). Interestingly, no significant
modulation in OC expression was induced in cells induced
for 7 days in OM (Figure 3(d)). The transcription factor OSX
was significantly upregulated, from day 2 on, in all treatment
groups compared to AdΨ5-treated cells, but displayed a
different trend of gene expression, with higher fold changes
in the OM-treated than in the LMP3-overexpressing groups,
at all tested time points (Figure 3(e)). Finally, the OP
gene resulted significantly upregulated exclusively at day 7
(FC: 4.4; P < 0.05) in AFSCs transduced with AdLMP-3
(Figure 3(f)).
LMP-3 overexpression in AFSCs was able to modulate
the expression of the Kruppel-like factors (KLF) genes. In
particular, a slight (less than 40% decrease) but significant
downregulation of both KLF4 (FC: 0.63; P < 0.05) and
KLF2 (FC: 0.68; P < 0.05) was observed as early as 24
hours post-transduction. Thereafter, a higher fold change
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Figure 2: Osteogenic differentiation in vitro. Alizarin Red staining performed 2 weeks after cell transduction, showing a red-colored
mineralized matrix in treated cells ((a) AdLMP-3) and negative staining in control cells ((b) AdΨ5).
decrease of KLF genes’ expression was observed in AFSCs 2,
4, and 7 days after AdLMP3 transduction (Figure 4(a)). In
particular, KLF4 expression was reduced by more than 80%
in both the day 2 and the day 4 groups (FC: 0.22 and 0.23,
resp.; Figure 4(a)). A lesser extent of gene downregulation
(FC: 0.59, i.e., around 40% decrease) was then observed
after 7 days. Conversely, the expression of KLF2 showed a
time-related trend as its expression levels decreased gradually
throughout the time course (Figure 4(a)).
3.4. LMP Silencing Induces KLF4 Upregulation. In order
to verify the direct regulatory effects of LMP on KLF-2
and -4, during the activation of the osteogenic cascade,
the expression of LMP gene has been transiently inhibited
in AFSCs. LMP silencing was efficient as gene expression
was significantly reduced by 55% (FC: 0.45) and 70% (FC:
0.26) 24 and 48 hours, respectively, after siRNA transfection
(Figure 5(a)). The expression levels of KLF genes in LMP-
silenced AFSCwas transiently modulated 24 hours after LMP
silencing. In particular, only the expression of KLF4 was
significantly (FC: 1.58; P < 0.05) upregulated in AFSCs,
while no significant change in KLF2 expression was observed
(Figure 5(b)). Thereafter, expression of both KLF genes was
not signficantly modified 48 hours after siRNA treatment
compared to controls (data not shown).
3.5. LMP3 Overexpression Does Not Induce the miR-143/145
Signaling. In order to verify the possible involvement of
the miR-143/145 cluster activation, in the LMP3-mediated
KLF4 repression, we have analyzed the expression of the
two microRNA in Ad-LMP3 transduced cells, 24 and 48
hours post-transduction, using untransduced and AdΨ5-
transduced cells as controls. Our results showed that miR-
145 was undetectable in AFSC in all experimental groups up
to 48 hours posttransfection. miR-143 was weakly expressed
in all experimental conditions only at 48 hours, but no
significant differential expression was observed between
AdLMP3-treated cells and controls (Figure 4(b)).
4. Discussion
Since their original isolation from rat calvarial bone in
1998 [24], lim mineralization proteins (LMPs) have been
employed to induce bone formation/healing in diverse
animal models along with the osteogenic differentiation
of mesoderm-derived cell types in vitro [1, 2, 23, 25,
33–39]. Three alternative transcript variants are spliced
from the same human gene (PDZ and LIM domain 7
(enigma), PDLIM7) giving rise to three protein isoforms,
namely, LMP1, LMP2, and LMP3 (Figure 6(a)). Although
the proteins are named after the presence of LIM conserved
domains, these are present in only LMP1 and LMP2
isoforms; while the PDZ domain is present in all the
three variants [26]. LIM domains are supposed not to be
required for the osteogenic properties of LMP, considering
that the osteogenic properties have been demonstrated only
for LMP1 and LMP3 [26, 27]. The nonconserved region of
the human LMP1 protein is represented by a 300-aminoacid
sequence (Figure 6(a)). This domain is only partially retained
in LMP3, due to the alternative splicing process that causes
the out-of-frame insertion of 17bp causing the introduction
of a premature stop codon [23]. The resulting protein shares
the first 133 aminoacids with LMP1, while is different in the
C-terminus. The full-length isoform (LMP1, Figure 6(a)) is
known to induce the expression of BMP and reinforce the
osteogenic effect of exogenous BMPs during ectopic bone
formation [35, 39]). LMP3 has been shown to induce ectopic
bone formation in mice, following either direct vector-
mediated gene transfer or using cell-based delivery, along
with efficient bone healing in a rat mandibular bone defect
model [1, 2, 23]. The molecular mechanisms underlying
LMP3 function have been partially elucidated, by analyzing
the consequences of transgenic expression in rodent cells,
including calvarial osteoblasts, murine preosteoblasts and
dermal fibroblasts [1, 23]. These studies allowed demonstrat-
ing that the molecular signaling initiated by LMP3 tends to
overlap with and amplify the BMP2-induced osteogenic cas-
cade, through the direct upregulation of both BMP2 and its
bone-specific target genes [23, 26]. We have recently shown
that the early phases of the molecular signaling induced by
LMP3 in human bone marrow-MSCs involve the activation
of the transforming growth factor β1 pathway, leading to
the regulation of cell proliferation and the induction of
muscular-skeletal tissue differentiation [22]. Taken together,
these data could suggest that LMP3 acts upstream to the
main osteogenic developmental signaling pathways.
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Figure 3: qPCR gene expression analysis. The graphic represents the expression levels of osteospecific gene ((a) BMP2; (b) RunX2; (c)
SMARCC2; (d) OC; (e) OSX; (f) OP). Values represent the mean of triplicate experiments for each time point tested. AdΨ5: mock-
transduced control cells; AdLMP-3: treated cells; OM: cells cultivated in osteogenic medium as positive controls; d: days after cell
transduction (4d-time point was not assessed in OM-cells); ∗: statistical significance, P < 0.05. Fold change was calculated according to
the 2−ΔΔCt method.
In this study, we have further demonstrated that LMP3
can induce the efficient osteogenic differentiation of mes-
enchymal cells isolated from amniotic fluid (AFSCs). Along
with other fetal tissues’ derived MSCs, AFSCs display more
“undifferentiated” features [3]. Recent data have indicated
that induced pluripotent stem cells (iPS) are more efficiently
generated from AF-derived cells rather than from human
somatic cells [40]. Thus, this cell type could represent a
suitable in vitro model for characterizing the basic molec-
ular events associated to the LMP-induced osteogenic cell
differentiation program [3, 11–13]. Our results demon-
strated that in AFSCs LMP3 induces a significant and
early transcriptional activation of SMARCC2, along with
BMP2, OC, OP, and the bone-specific transcription factors
RUNX2 (CBFA1) and OSX. SMARCC2 encodes a poorly
characterized member of the SWI/SNF chromatin remodel-
ing complex necessary for the osteogenic differentiation of
mesenchymal cells trough the BMP2/RunX2 pathway [29].
The effects of LMP3 on BMP2, RUNX2, and SMARCC2
gene expression was even stronger than those induced by the
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Figure 4: KLF genes expression analysis. Values represent the mean
of triplicate experiments for each time point tested, namely, 2, 4,
and 7 days after AdLMP3-mediated cell transduction; Ψ5: control
sample represented by mock-transduced cells. Fold change was
calculated according to the 2−ΔΔCt method. ∗: statistical significance
(P < 0.05).
standard osteogenic induction in AFSC cultures. Based on
previous observations, it could be speculated that the over-
expression of LMP3 gene tends to amplify the downstream
effects on target genes, through the activation of the TGFβ
and BMP2 osteogenic pathways [1, 22], Figure 6(b)).
Our results also showed that LMP3 displays an inhibitory
effect on KLF-4 gene expression. KLF genes encode a subclass
of the zinc-finger family of transcription factors implicated
in the regulation of cell growth and differentiation, acting on
the cell cycle checkpoints [21, 30, 31]. Particularly, KLF4 is
implicated in maintaining stem cells in an undifferentiated
status and is able to mediate cancer cells proliferation,
migration, and invasion [30, 31, 41]. The combination of
KLF4 with other core-transcription factors (namely OCT4,
SOX2, and c-MYC) define the “OSKM” gene network,
widely used for reprogramming somatic cell and generate
iPS [42–44]. We have recently demonstrated a role of
KLF4 in defining the gene expression signature associated
to MSC stemness maintenance [21]. Although a specific
role for KLF4 in AFSC biology and homeostasis has not
been yet demonstrated, the possibility of efficiently inducing
iPS from amniotic fluid-derived cells through OSKM gene
overexpression could reasonably corroborate this hypothesis
[40, 45, 46].
KLF4 was also found to be implicated in the TGFβ-
dependent regulation of smooth muscle cell differentiation;
TGFβ downregulates KLF4, which, on its turn, represses
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Figure 5: Gene expression analysis upon LMP silencing. The
histogram represents the relative expression levels of LMP (24
and 48 hours following siRNA transfection, (a)), KLF2 and KLF4
(24 hours after LMP silencing, (b)). Values represent the mean
of triplicate experiments for each test. SHAM: cells treated with
transfection reagent alone; Neg Ctrl: cells transfected with AllStars
Negative Control SiRNA; SiRNA-LMP: cells treated with SiRNA-
LMP construct; RQ: relative quantity, calculated according to 2−ΔΔCt
method; ∗: statistically significant (P < 0.01).
the TGF β-dependent increase in differentiation markers
[47–49]. In the same cells, KLF4 was also found to
induce the expression of the TGFβ receptor I and the
activation of Smad2/3—p38 MAPK signaling, suggesting
the existence of a feed-back loop implicated in the cell
differentiation program [50]. Based on such evidences,
the KLF4 downregulation described in this study could
be considered among the basic molecular effects induced
by LMP3 during the osteogenic commitment of AFSCs.
Infact, upon LMP silencing, KLF4 expression transiently
increased, suggesting that the osteogenic effects of LMP
on AFSCs could be mediated, at least in part, by the
inhibition of KLF4. We have previously shown that LMP3
induces the early transcriptional activation of TGFβ1 and
related signaling pathway [22], which is known to underlie
osteoblast differentiation of MSC [51]. Taken together, these
data could suggest that LMP3-mediated osteogenic signaling
implies the induction of TGF β1 that, on its turn, may induce
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Figure 6: LMP domains and hypothetical signaling pathway.LMP1 and LMP3 are the osteogenic isoforms resulting from the alternative
splicing of the PDLIM7 gene. (a) Both proteins share a conserved PDZ domain and a supposed osteogenic region which comprises two
separate domains which interact with the SMURF1 WW2 domain (Sangadala et al, 2006). Three conserved LIM domains are present in
the C-terminus of LMP1 while are absent in LMP3 due to its premature termination as a consequence of an out-of-frame insertion during
splicing (see text for details). A scheme of the hypothetic molecular signaling induced by LMP3 in AFSC is proposed in (b) LMP3 induces
the expression of the osteogenic transcription factors OSX and RUNX2, along with the osteogenic markers OC and OP. SMARCC2, involved
in chromatin remodeling, is also a transcriptional target of LMP3, according to our results. LMP3 upregulates BMP2 that, on its turn,
binds its surface receptor. This event induces the activating phosphorilation of SMADs that translocate to the nucleus to induce RUNX2,
leading to the transcriptional induction of bone-specific genes mediating the osteogenic cascade. Conversely the KLF4 transcription factor is
downregulated by LMP3. Also TGFβ, induced by LMP3 in bone marrow-derived MSCs (Bernardini et al, 2010) represses KLF4 expression,
by inducing the miR143-145 cluster (Davis-Dusenbery et al, 2011), which resulted unaffected by LMP3 overexpression. A + sign inducate
positive regulation, a – sign indicate negative regulation on the arrows and lines; EC: extracellular compartment.
KLF4 downregulation. It was recently demonstrated that
TGFβ induces KLF4 repression through the transcriptional
activation of two microRNAs (miR-143/miR145), during the
terminal differentiation of vascular smooth muscle cells [52].
No data so far described the possible involvement of the
TGFβ-miR143/145-KLF4 pathway in the molecular network
underlying the osteogenic process. Our results indicated that
mir143/145 were not involved in the LMP3-mediated KLF4
modulation, suggesting that an alternative pathway should
be activated during the osteogenic commitment of AFSC.
Interestingly, no significant modulation of BMP2,
RUNX2 and OSX gene expression occurred among the early
molecular events induced by LMP3 overexpression in AFSC.
This evidence is coherent with the early molecular profile
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observed in bone-marrow-derived MSC transduced with
AdLMP3 [22]. This evidence may suggest that the activation
of the TGFβ cascade is initiated by LMP through a BMP2-
independent mechanism, which may deserve further close
examination.
The longer LMP isoform, LMP1, was recently described
as a downstream target gene of TGFβ1, essential for the pro-
liferation and differentiation of periodontal ligament pro-
genitor cells [53]. These evidences may suggest the existence
of a reciprocal feedback control between LMP molecules
and TGFβ1 during cell replication and/or differentiation that
may also implicate the transcriptional modulation of KLF4.
Based on such observations, a clearer insight into the LMP3-
TGF interaction should be obtained in further studies, in
order to delineate the correct molecular steps involved in the
LMP-dependent osteogenic cascade.
Our results showed also that another KLF gene, KLF2,
was apparently modulated during LMP3-induced osteogenic
differentiation of AFSC, although it was not significantly
modulated following LMP silencing. This suggested that
KLF2 should not be directly regulated at the transcriptional
level by LMP. KLF2 is one of the core transcription
factors implicated in embryonic stem cells maintenance,
self-renewal and pluripotency [54–56]. It has been recently
demonstrated that KLF2 inhibits adipogenesis andmonocyte
differentiation [57–59] and governs specific developmental
steps in different tissues [60, 61]. Although no clear evidence
has suggested so far that KLF2 may affect osteogenic
differentiation, it could be hypothesized that the KLF2
downregulation observed in LMP-overexpressing AFSCs
could be a consequence of the cell differentiation process.
5. Conclusions
This study proposes some additional hints towards the
functional characterization of LMP, which only recently
emerged as an efficient osteogenic molecule. Based on the
original data obtained in this study, the involvement of an
alternative signaling, within the osteogenic cascade induced
by LMP, could be assumed. This hypothesis may deserve ad
hoc further investigations. Considering the easy retrieval of
AFSCs and the lack of major invasiveness and ethical issues of
the proposed isolation protocol, these results could provide a
convincing proof-of-principle for the potential development
of future autologous cell-based therapies based on these cells,
to be employed for bone regeneration/healing purposes also
in perinatal applications.
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